Indeed, inhibiting the binding of TNFR2 and its ligand TNF-α through high-affinity antibodies, especially in the CRD regions where both proteins interact the most, is crucial to eliminating the burden of TNFR2 as an immunosuppressive protein in the BC TME. The gene discussed is TNF; the disease is breast cancer.